

**REMARKS**

By the foregoing amendment to the specification, the Applicants have replaced the Sequence Listing of record with a substitute Sequence Listing. The Applicants request entry of the foregoing amendment to correct the Sequence Listing filed as part of the specification in the above-identified application. Accompanying the paper copy of the substitute Sequence Listing is a computer readable version of the substitute Sequence Listing as well as a "Statement Pursuant to 37 C.F.R. §§ 1.825(a) and (b)." The Applicants submit that no new matter has been added by the substitute Sequence Listing.

The Applicants have corrected the errors in the sequence listing cited by the Examiner. More specifically, the amino acid numbering was corrected in SEQ ID NOS: 1, 2, 3, 4, 5, 6, 15 and 19, and the "n" at nucleotide positions 662 and 668 of SEQ ID NO: 18 have been defined as any of nucleotides a, c, g, or t.


**CONCLUSION**

The Commissioner is hereby authorized to charge any deficiency in the fee to our Deposit Account No. 13-2855, under Order No. 01017/35966B. A copy of this paper is enclosed. Should the Examiner have any questions or comments regarding this response or the application, the Examiner is invited to contact the undersigned at the number indicated.

Respectfully submitted,

MARSHALL, GERSTEIN & BORUN LLP  
6300 Sears Tower  
233 South Wacker Drive  
Chicago, Illinois 60606-6357  
(312) 474-6300

By:

  
Lynn L. Danulis, Ph.D.  
Registration No. 53,066  
Agent for Applicants

May 25, 2004